Study: NCT01384734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 400 mg
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 800 mg
Description: Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 600 mg
Description: Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 1200 mg
Description: Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400 mg
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 300 mg
Description: Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 300 mg
Description: Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 300 mg
Description: Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 300 mg
Description: Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir 300 mg
Description: Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir 100 mg
Description: Tablets, Oral, 100 mg, Once daily, 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir 300 mg
Description: Capsules, Oral, 300 mg, Once daily, 96 weeks